Dr Coleman is a distinguished scientist, entrepreneur, biotech CEO, and company builder who brings a wealth of experience in driving ground-breaking platform technologies from initial innovation to Phase 3 clinical trials and beyond. Dr Coleman has focused on early- and late-stage development of viral-based vaccines and therapeutics, raising more than $120 million in public and private financing. Dr Coleman has a honed ability to maximize shareholder value through creative and thoughtful management of multi-asset/multi-disciplinary pipelines.